You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
News on microarrays, multiplexing, genotyping, cytogenetics, gene expression profiling in genetics, genomics, and molecular diagnostics.
The European Commission recently awarded the company a two-year, €2.6 million Horizon 2020 grant to achieve its ambitions.
Tempus' test is a modified version of Thermo Fisher Scientific's Applied Biosystems TaqPath COVID-19 Combo Kit, which previously received EUA from the FDA.
Funding from RADx and NIAID will enable the scale-up of multiplexed viral detection microarrays to 4 million tests per month.
The Oslo-based company plans to develop a test that can identify high-risk individuals based on an epigenetic signature.
Attomarker said that it aims to develop a miniaturized version of the test that works with a smartphone to enable point-of-care and at-home testing.